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ABSTRACT
Y-box binding protein 1 [YBX1] is a multifunctional protein known to facilitate 
many of the hallmarks of cancer. Elevated levels of YBX1 protein are highly 
correlated with cancer progression, making it an excellent marker in cancer. The 
connection between YBX1 and the important nuclear factor κB [NF-κB] has never 
been reported. Here, we show that overexpression of wild type YBX1 [WT-YBX1] 
activates NF-κB, suggesting that YBX1 is a potential NF-κB activator. Furthermore, 
using mass spectrometry analysis we identified novel phosphorylation of serine 165 
[S165] on YBX1. Overexpression of the S165A-YBX1 mutant in either HEK293 cells 
or colon cancer HT29 cells showed dramatically reduced NF-κB activating ability as 
compared with that of WT-YBX1, confirming that S165 phosphorylation is critical for 
the activation of NF-κB by YBX1. We also show that expression of the S165A-YBX1 
mutant dramatically decreased the expression of NF-κB-inducible genes, reduced 
cell growth, and compromised tumorigenic ability as compared with WT-YBX1. Taken 
together, we provide the first evidence that YBX1 functions as a tumor promoter via 
NF-κB activation, and phosphorylation of S165 of YBX1 is critical for this function. 
Therefore, our important discovery may lead to blocking S165 phosphorylation as a 
potential therapeutic strategy to treat colon cancer. 
INTRODUCTION
Y-box binding protein [YBX1], also known as 
nuclease-sensitive element-binding protein [NSEP1] or 
DNA-binding protein B [DBPB] is encoded by the YBX1 
gene. YBX1 contains a highly conserved “cold-shock” 
domain [CSD] and is a member of the CSD superfamily. 
YBX1 is a multifunctional DNA/RNA-binding protein 
that regulates transcription and translation. The CSD of 
YBX1 specifically interacts with DNA and RNA and 
regulates many DNA- and mRNA-dependent processes, 
including DNA transcription, replication, repair, 
environmental stress, chromatin remodeling, as well as 
pre-mRNA splicing, etc. [1]. 
High expression of YBX1 is frequently detected 
in a wide variety of cancers and closely relates to the 
progression and poor prognosis of these cancers. Elevated 
levels of YBX1 are seen in melanoma, osteosarcomas, 
prostate, breast, squamous cell, lung, ovarian, thyroid, 
and colorectal [CRC] cancers [2, 3]. Shibao K et al [4] 
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first demonstrated that YBX1 expression is elevated in 
CRC and positively correlates with DNA topoisomerase 
II α and proliferating cell nuclear antigen [PCNA] 
expression but not with multi-drug resistance gene 
[MDR1]. Later, Vaiman et al [5] showed that in colon 
cancer cells, YBX1 accumulates in the nuclei in response 
to the chemotherapy drug vinblastine and is associated 
with development of vinblastine resistance and elevated 
expression of P-MDR1. YBX1 promotes tumorigenesis, 
cell proliferation, replicative immortality, angiogenesis, 
invasion, and metastasis, most of which are the ‘hallmarks 
of cancer’ proposed by Hanahan and Weinberg [6, 7]. 
Furthermore, Lee C et al [8] showed that, YBX1 protein, 
when knocked down using RNAi, reduces tumor growth in 
human epidermal growth factor receptor [HER-2] positive 
breast cancer cells, confirming that YBX1 functions 
as a tumor promoter in breast cancer. It is now widely 
accepted that YBX1 is an oncogene. It has been previously 
demonstrated that the phosphatidylinositide 3-kinase 
[PI3K/AKT] pathway causes the phosphorylation of S102 
on YBX1 protein and governs its nuclear translocation 
in breast cancer cells [9, 10]. When this site is disrupted, 
YBX1 is unable to translocate to the nucleus and activate 
the target genes, leading to a reduction in tumor growth in 
human breast cancer cells [10-12]. 
NF-κB is a family of transcription factors 
that regulates the expression of genes involved in 
inflammation, cell proliferation, differentiation, and 
survival of immune responses [13]. Constitutively active 
NF-κB has been found in multiple types of cancer [14, 
15]. There are five proteins in the mammalian NF-κB 
family: RelA [p65], RelB, c-Rel, p50/p105 and p52/p100. 
All proteins in the NF-κB family share a Rel homology 
domain [RHD] in their N-terminus, which results in their 
classification as NF-κB/Rel proteins. RHD is essential 
for dimerization as well as for binding to cognate DNA 
elements. The prototypic NF-κB is the heterodimer of 
p65 and p50. The activity of NF-κB is primarily regulated 
by interaction with inhibitory IκB [inhibitor of NF-
κB] proteins. In most cells, NF-κB is present as a latent 
and inactive IκB-bound complex in the cytoplasm [16]. 
When a cell receives any of a multitude of extracellular 
signals such as stress, cytokines, free radicals, radiation 
etc., NF-κB rapidly enters the nucleus and activates target 
gene expression [17]. The molecular identification of p65 
subunit as a member of the reticuloendotheliosis (REL) 
family provided the first evidence that linked NF-κB to 
cancer, as v-REL is an oncoprotein of the REL retrovirus 
(REV-T) [18]. NF-κB therefore holds great potential for 
use as a therapeutic target.
Although there has been increasing evidence that 
YBX1 and NF-κB could co-regulate different families of 
genes like cyclin, TGF-β etc [www.evexdb.org], to date 
it is unknown if YBX1 can activate NF-κB directly. In 
the study described here, we found that overexpression 
of WT-YBX1 could activate NF-κB. This is the first 
evidence suggesting that YBX1 is an activator of NF-
κB. Using mass spectrometry analysis, we identified 
phosphorylation of the novel S165 site on YBX1. 
Overexpression of S165A-YBX1 mutant led to decreased 
NF-κB inducible gene expression, as well as reduced cell 
growth and tumorigenic ability as compared with the 
effect of the overexpression of WT-YBX1. We proposed 
that phosphorylation of S165 on YBX1 is essential for the 
biological function of YBX1. Thus, we provided a novel 
mechanism for the regulation of YBX1, which can be used 
as a potential strategy to control YBX1 and further lead to 
down-regulation of the activity of NF-κB in cancer. 
RESULTS
Identification of novel phosphorylation 
modification on S165 of YBX1
To date, YBX1 has been shown to be phosphorylated 
only on S102 after insulin growth factor 1 (IGF-1) 
treatment [10], an event that fundamentally affects YBX1 
function in human breast cancer MCF7 cells [10, 11]. 
Since it is very common that the same protein can be 
phosphorylated on different amino acids, such as serine, 
threonine [T], and tyrosine [Y], or on different residues in 
response to different stimuli or in different cell systems, 
we wondered whether treating 293 cells with well-
known NF-κB activating cytokine IL-1β would lead to 
differential phosphorylation of YBX1. In order to screen 
for phosphorylation sites on YBX1, 293 cells with stable 
expression of Flag-tagged WT-YBX1 were treated with 
IL-1β for 1h, and anti-Flag-antibody was used to pull 
down Flag-WT-YBX1. As shown in Figure 1A, a strong 
YBX1 band was obtained in a GelCode blue stained gel. 
This band was excised and further analyzed by MS assay, 
revealing that YBX1 is phosphorylated on S165 residue 
upon the treatment with IL-1β. In contrast, no S102 
phosphorylation was observed in this sample (Figure 
1B). We then treated 293 cells with IL-1β for different 
times, and treated breast cancer MCF7 cells with IGF-1 
for 1h. Western assay (Figure 1C) further confirmed that in 
response to IL-1β, no S102 phosphorylation was induced 
in IL-1β treated 293 cells, while a strong pS102 signal 
was observed in IGF1 treated MCF7 cells. This interesting 
finding confirmed the differential phosphorylation of 
distinct sites of YBX1 in separate experimental systems, 
leading us to further investigate the significance of S165 
phosphorylation on the function of YBX1.
S165 phosphorylation of YBX1 is essential for the 
activation of NF-κB
Although YBX1 is a known oncogene, to date 
no publications have shown that YBX1 could directly 
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Figure 1: Identification of phosphorylation of S165 on YBX1. A. SDS-PAGE gel stained with GelCode blue, showing a strong 
Flag-tagged YBX1 band that was pulled down using anti-Flag antibody via co-immunoprecipitation. B. Mass Spectrometry data for YBX1, 
showing that in response to IL-1β treatment, serine 165 (S165) is phosphorylated. A mass shift of 80Da was observed, indicating the 
existence of phosphorylation modification. C. Western blot, showing that S102 is not phosphorylated in 293 cells upon IL-1β stimulation. 
In contrast, S102 is phosphorylated in breast cancer MCF7 cells upon IGF-1 treatment. 
Oncotarget29399www.impactjournals.com/oncotarget
activate NF-κB in mammalian cells. Since NF-κB is 
frequently activated in cancer, we would like to examine 
whether YBX1 is an activator of NF-κB and whether 
phosphorylation of S165 plays a critical role in this 
process. In order to test this possibility, we used a pool of 
shRNAs to knockdown the expression of YBX1 protein in 
293 cells (Figure 2A, left panel) or overexpressed either 
WT-YBX1 or S165A-YBX1 (Figure 2A, right panel). 
A NF-κB luciferase assay was carried out to determine 
the effect of YBX1 on NF-κB activation. As shown in 
Figure 2B, top panel, treating 293 cells with IL-1β greatly 
increased NF-κB activity, while knocking down the 
expression of YBX1 greatly reduced this effect, suggesting 
that YBX1 is a critical activator in IL-1β-induced NF-κB 
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Figure 2: YBX1 is an activator of NF-κB and phosphorylation of S165 is critical for its NF-κB activating ability. A. 
Western Blot, left panel, showing that YBX1 is knocked down by shRNAs. Right panel, showing that both wild type (WT-) YBX1 and 
mutant S165A-YBX1 were overexpressed at similar levels in 293 cells. B. κB-specific luciferase assay in 293 cells, top panel, NF-κB 
luciferase assay, showing that knockdown of YBX1 decreased IL-1β-induced NF-κB activation. The data represent the means ± SD from 
three independent experiments. *P < 0.05 vs. Ctrl group; #P < 0.05 vs. Ctrl+IL-1β group. Bottom panel inset, showing that overexpression 
of WT-YBX1 could activate NF-κB, while overexpression of S165A-YBX1 dramatically reduced NF-κB activation. Bottom panel main 
figure, showing that overexpression of WT-YBX1 could further enhance IL-1β-induced NF-κB activation, while overexpression of mutant 
S165A-YBX1 led to significantly lower NF-κB activation as compared to that of WT-YBX1. The data represent the means ± SD from three 
independent experiments. * P < 0.05 vs. Ctrl group; # P < 0.05 vs. WT-YBX1 group. C. κB-specific luciferase assay, showing that either 
WT-P65 or WT-YBX1 could activate NF-κB respectively. Additionally, WT-P65 and WT-YBX1 have synergistic effect on the activation of 
NF-κB. Mutant S165A-YBX1 showed much compromised ability for this synergistic effect. The data represent the means ± SD from three 
independent experiments. *P < 0.05 vs. Ctrl group. #P < 0.05 vs. WT-P65 group. $P < 0.05 vs. WT-P65/WT-YBX1 group. D. Western Blot 
in colon cancer HT29 cells, top left panel, showing that YBX1 was successfully knocked down by a pool of YBX1 specific shRNAs. Top 
right panel, showing that both WT-YBX1 and mutant S165A-YBX1 were overexpressed at similar levels in HT29 cells. Anti-Flag antibody 
was also used to show that both Flag-tagged WT-YBX1 and S165A-YBX1 was expressed at similar levels. Bottom left panel, showing that 
using shRNA to knock down YBX1 decreased NF-κB activity as compared to the HT29 control cells. The data represent the means ± SD 
for three independent experiments. *P < 0.01 vs. Ctrl group. Bottom right panel, κB-specific luciferase assay, showing that overexpression 
of mutant S165A-YBX1 led to decreased NF-κB activity as compared to that of WT-YBX1 cells. . The data represent the means ± SD for 
three independent experiments. *P < 0.01 vs. Ctrl group; #P < 0.01 vs. WT-YBX1 group. 
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activation. Furthermore, overexpression of WT-YBX1 
activated NF-κB, while overexpression of S165A-
YBX1 mutant showed much reduced NF-κB activation 
as compared with WT-YBX1 (Figure 2B, bottom panel, 
Figure 3: Phosphorylation of S165 is critical for the expression of a subgroup of NF-κB target genes. A. Comparative 
analysis of YBX1-S165A mutant with WT-YBX1 overexpressing cells on YBX-inducible NF-κB target genes. B. A short list of typical 
NF-κB inducible genes that can be up regulated by WT-YBX1 but not by YBX1-S165A. C. Quantitative PCR (qPCR) analysis, showing 
confirmation of microarray data. Three genes: OSM, PFKB2, and TRIM14 show reduced gene expression in the mutant S165A-YBX1 as 
compared to that of WT-YBX1. The data represent the means ± SD from three independent experiments. *P < 0.05 vs. Ctrl group; #P < 
0.05 vs. WT-YBX1 group. D. qPCR analysis, showing that PFKB2, OSM and TRIM14 genes were strongly induced upon IL-1β treatment. 
This effect was further augmented by the overexpression of WT-YBX1. However, the expression of these genes were greatly decreased 
upon shRNA knockdown of YBX1. The data represent the means ± SD for three independent experiments. *P < 0.01 vs. Ctrl group; #P < 
0.01 vs. WT-YBX1 group; $P < 0.05 vs. WT-YBX1 group, with IL-1β treatment.
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inset). Impressively, this difference was further enhanced 
after three cell lines, 293 ctrl, WT-, and S165A-YBX1 
cells, were further treated with IL-1β (Figure 2B, bottom 
panel, main figure), strongly suggesting that YBX1 is 
an activator of NF-κB, and phosphorylation of S165 
plays a critical role in this function. Additionally, we 
overexpressed the WT-P65 subunit to activate NF-κB, a 
well-known phenomenon that has been previously reported 
[20]. As shown in Figure 2C, while sole overexpression of 
WT-YBX1 activated NF-κB, co-expression of both WT-
YBX1 with WT-P65 led to synergic activation of NF-κB. 
In contrast, S165A-YBX1 had greatly reduced ability to 
activate NF-κB when expressed alone or together with 
WT-P65. Collectively, this data confirmed that S165 is 
important for NF-κB activation by YBX1 in 293 cells.
We previously reported that many types of cancer 
cells, including colon cancer HT29 cells, have constitutive 
NF-κB activity [20]. Since YBX1 is a tumor promoter, we 
wanted to examine whether YBX1 functions as a NF-κB 
activator in cancer cells. We used shRNA to knock down 
YBX1 (Figure 2D, top left panel) and we overexpressed 
either WT-YBX1 or S165A-YBX1 at similar levels in 
HT29 cells (Figure 2D, top right panel). A luciferase assay 
was carried out as described above. As shown in Figure 
2D, knocking down YBX1 reduced the activity of NF-κB 
[bottom left panel], while overexpression of WT-YBX1 
but not mutant S165A-YBX1 significantly increased the 
activity of NF-κB [bottom right panel]. Taken together, 
both the shRNA data and the overexpression data 
confirmed that YBX1 is an activator of NF-κB and S165 
is critical for this activation in HT29 cells.
Phosphorylation of YBX1 on S165 is critical for 
NF-κB regulated gene expression
As post-translational modification of transcription 
factors is frequently related to differential gene expression 
[21], we examined how S165A mutation may affect 
NF-κB regulated gene expression. 293 cells with the 
overexpression of WT- or S165A-YBX1 were used to 
carry out Illumina microarray analysis. As shown in 
Figure 3A, compared with WT-YBX1, around 33% [185 
genes] of NF-κB target genes were downregulated by two-
fold or more in the cells expressing the S165A-YBX1 
mutant protein. The remaining 66% of the genes were 
not significantly affected. A short list of representative 
genes that are downregulated by S165A-YBX1 is shown 
in Figure 3B. These genes include cytokines, chemokines, 
and signaling components that may be involved in 
tumorigenesis and metastasis, suggesting the important 
role that S165A-YBX1 may play in cancer. Several genes 
were further confirmed by performing qPCR analysis, 
including gene encoding the 6-phosphofructo-2-kinase 
[PFKB2], an enzyme that participates in fructose and 
mannose metabolism; gene encoding oncostatin M [OSM], 
a pleiotropic cytokine that belongs to the interleukin 6 
group of cytokines; and gene encoding the tripartite motif-
containing 14 [TRIM14], a member of TRIM proteins 
family that are involved in pathogen-recognition and 
regulation of transcriptional pathways in host defense. 
These genes showed reduced expression in the S165A-
YBX1 mutant, as compared with the WT-YBX1 in 293 
cells (Figure 3C), demonstrating that phosphorylation 
of YBX1 at S165 is critical for the activation of NF-
κB-inducible genes. We further determined the effect 
of shRNA knockdown of YBX1 on the expression of 
these genes. As shown in Figure 3D, expression levels of 
PFKB2, OSM, and TRIM4 were strongly induced upon 
IL-1β treatment. This effect was further augmented by the 
overexpression of YBX1. However, using shRNA to knock 
down YBX1 significantly decreased the expression of 
these genes in the presence or absence of IL-1β treatment, 
confirming that YBX1 is important for the expression of 
these genes. Collectively, these data strongly supported the 
notion that phosphorylation of S165 on YBX1 plays an 
important role in NF-κB-inducible gene expression. 
Phosphorylation of S165 is critical for cell 
proliferation and tumor promoter activity in 
colon cancer HT29 cells
In order to determine the effect of S165 
phosphorylation on tumor promoter activity, cell growth 
was tested in colon cancer HT29 control, WT-YBX1, 
or S165A overexpressing stable cell lines. As shown 
in Figure 4A, left panel, knockdown of YBX1 greatly 
reduced cell growth, while overexpression of WT-
YBX1 but not S165A-YBX1 mutant promoted cell 
growth, suggesting that YBX1 is critical for HT29 cell 
growth. To evaluate how YBX1 interplays with P65 in 
cell growth, we further knocked down the expression 
of P65 in the above group of cells. As shown in Figure 
4A, right panel, cells grew significantly slower after P65 
knockdown in all groups. Overexpression of neither 
WT-YBX1 nor S165-YBX1 could significantly rescue 
this phenotype, suggesting that YBX1 promoted cell 
growth via the interplay with P65. We further carried 
out soft agar assay for the groups of cells described 
above. Similarly, we observed that overexpression of 
WT-YBX1 but not S165A could dramatically promote 
colony formation. Using shRNAs to knockdown YBX1 
greatly reduced colony formation (Figure 4B, top panel, 
top row, bottom left panel). Furthermore, knockdown of 
P65 with shRNA greatly diminished colony formation. 
Further overexpression of neither WT-YBX1 nor S165A 
could rescue this phenotype (Figure 4B, top panel, bottom 
row, bottom right panel). Collectively, the above findings 
suggest that S165 phosphorylation of YBX1 is critical for 
this function.
We also generated 293 cell lines overexpressing 
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Figure 4: Phosphorylation of S165 of YBX1 is important for cell growth and colony independent growth in colon cancer 
HT29 cells. A. Cell growth assay, left panel, showing that, compared to the HT29 control cells [symbol: solid square], overexpression 
of WT-YBX1 [symbol: solid triangle] promote cell growth, while overexpression of S165A-YBX1 [symbol: cross] or knockdown of 
YBX1 [symbol: solid diamond] failed to do so. The data represent the means ± SD from three independent experiments. *P < 0.05 vs. 
Ctrl group; #P < 0.05 vs. WT-YBX1 group. Right panel, showing that knockdown of P65 subunit of NF-κB decreased HT29 cell growth, 
while overexpression of WT-YBX1 [symbol: triangle] but not S165A-YBX1 [symbol, square] could partially rescue cell growth in shP65 
knockdown cells. The data represent the means ± SD from three independent experiments. *P < 0.05 vs. Ctrl group. B. Soft agar assay, 
top row and bottom left panel, showing that overexpression of WT-YBX1 increases the size of colonies whereas knockdown of YBX1 
showed the opposite effect in HT29 cells. Overexpression of S165A-YBX1 mutant showed decreased colony size as compared to that of 
WT-YBX1. Bottom row and bottom right panel, showing that knockdown of the P65 subunit of NF-κB decreased the size of colonies, 
while overexpression of either WT-YBX1 or S165-YBX1 could not rescue this phenotype. Bottom panel, quantification of colony number 
and colony size respectively for the soft agar assay. The data represent the means ± SD from three independent experiments. *P < 0.01 
vs. Ctrl group. #P < 0.01 vs. WT-YBX1 group C. Left panel, Western assay, showing the expression levels of P65, WT-YBX1 or S165A-
YBX1 after transient transfection in 293 cells. Right panel, cell growth was tested in the transfected cells. Overexpression of either P65 
[symbol, square] or WT-YBX1 [symbol, triangle] but not S165A-YBX1 mutant [symbol, cross] significantly promoted cell growth. Co-
overexpression of WT-P65 with WT-YBX1 [symbol, plus] but not S165A-YBX1 [symbol, circle] showed dramatically synergistic effect 
on cell growth. The data represent the means ± SD from three independent experiments. *P < 0.05 WT-P65 or WT-YBX1 or S165A vs. Ctrl 
group, # P < 0.01 WT-P65+WT-YBX1 group vs WT-P65.
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WT-P65 or WT-YBX1 or S165A-YBX1 (Figure 4C, left 
panel). Cell growth was further tested in these groups of 
cells. As shown in Figure 4C, right panel, overexpression 
of WT-P65 or WT-YBX1 but not the S165A mutant 
protein led to a significant increase in cell growth. Co-
overexpression of WT-YBX1 but not S165A-YBX1 
mutant with WT-P65 synergistically promoted cell growth. 
This data supported the notion that S165 phosphorylation 
of YBX1 is critical for promoting NF-κB-dependent cell 
growth by YBX1. 
YBX1 works downstream of IκBα
IκBα degradation is a critical step in the activation 
of NF-κB triggered by cytokines such as IL-1β. Therefore, 
we treated either 293 (Figure 5A) or HT29 cells (Figure 
5B) with the overexpression of WT-YBX1 or S165A-
YBX1 mutant cells with IL-1β for different times to 
examine the effect of S165A-YBX1 on the degradation 
of IκBα as compared with that of WT-YBX1. As shown 
in Figure 5A, 5B, the NF-κB signaling pathway was 
activated by the degradation of IκB in a similar fashion 
in all the cell lines including control, WT-YBX1, and 
S165A-YBX1 upon IL-1β treatment. This result suggests 
that YBX1 may work downstream of IBα.
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Figure 5: Activation of NF-κB by YBX1 functions downstream of IκBα degradation. [A, B] Western Blot analyses, 
showing that overexpression of either WT-YBX1 or S165A-YBX1 did not affect the degradation of IκBα, suggesting that YBX1 functions 
downstream of IκBα degradation. C. EMSA assay, showing the overexpression of WT-YBX1 but not S165A-YBX1 enhanced NF-κB DNA 
binding ability upon IL-1β treatment, suggesting that phosphorylation of S165-YBX1 may enhance NF-κB DNA binding ability in nucleus. 
D. Immunofluorescence [IF] staining, showing the distribution of overexpressed WT-YBX1-Flag and S165A-YBX1-Flag in 293 cells. In 
untreated WT-YBX1 cells, YBX1 was located mainly in cytoplasm, but partly translocated into the nucleus after IL-1β treatment. However, 
YBX1 translocation was not observed in S165A-YBX1 mutant cells, before or after IL-1β treatment, suggesting that phosphorylation 
at S165 plays an important role in mediating the nuclear translocation of YBX1. DAPI was used for nuclear staining. E. IF experiment, 
showing that YBX1 co-localize with p65. IF experiment was carried out in 293, 293-WT-YBX1-Flag and S165A-YBX1-Flag stable cell 
lines. Anti-Flag was used to detect YBX1-Flag protein [green] and p65 antibody was used to detect endogenous P65 [red]. In 293 control 
cells, endogenous P65 is mainly located in cytoplasm while upon IL-1β treatment, P65 was observed in both cytoplasm and nucleus. No 
Flag-tagged YBX1 was observed in 293 cells. In WT-YBX1-Flag group, both Flag tagged YBX1 and endogenous p65 are located mainly 
in cytoplasm, but partly translocated into nuclear after IL-1β treatment and co-localized in nucleus. However, YBX translocation was not 
observed in S165A-YBX1-Flag cells, indicating that S165A eliminates YBX nuclear translocation ability. DAPI was used for nuclear 
staining.
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We then tested whether YBX1 affects NF-κB DNA 
binding ability. κB-specific EMSA analysis was carried 
out in 293 cells with overexpression of either WT-YBX1 
or S165A-YBX1 proteins. As shown in Figure 5C, 
NF-κB DNA binding was greatly induced upon IL-1β 
treatment, confirming our previously reported finding [21]. 
Moreover, overexpression of WT-YBX1 but not S165A-
YBX1 substantially enhanced IL-1β-induced κB binding 
ability, suggesting that S165 phosphorylation is critical for 
enhancing NF-κB DNA binding by YBX1 (Figure 5C).
How is YBX1 distributed in cells? Nuclear 
shuttling of YBX1 has been associated with its increased 
tumor promoter activity, and has been shown to occur 
upon stimulation with IL-1β [22]. In order to establish 
if phosphorylation at S165 is important for the nuclear 
shuttling of YBX1, we carried out an immunofluorescence 
[IF] experiment to check for Flag-tagged YBX1 
localization. As visualized in Figure 5D, WT-YBX1 was 
mainly located in the cytoplasm, but partially translocated 
to the nucleus after IL-1β treatment. However, in S165A-
YBX1 cells, S165A-YBX1 was mainly localized in the 
cytoplasm before and after IL-1β treatment, indicating that 
phosphorylation at S165 plays a critical role in mediating 
the nuclear translocation of YBX1. 
We further carried out the IF experiments to 
examine the possibility of co-localization of WT-YBX1 
and P65. 293, 293-WT-YBX1 and S165A stable cell lines 
were used as models. Flag antibody was used to detect 
Flag-tagged YBX1 [green], and P65 antibody [red] was 
used to detect endogenous p65. DAPI was used for nuclear 
staining. As observed in Figure 5E, endogenous p65 
was mainly located in cytoplasm in non-stimulated 293 
control cells. Upon IL-1β treatment, P65 was redistributed 
in both cytoplasm and nucleus. As expected, no Flag-
tagged YBX1 was observed in 293 control cells. In WT-
YBX1 overexpressing cells, both Flag-tagged YBX1 and 
endogenous P65 were mainly located in the cytoplasm, but 
partially translocated and co-localized in the nucleus after 
IL-1β treatment. On the other hand, YBX1 translocation 
was not observed in S165A-YBX1 cell lines in the 
absence or presence of IL-1β treatment, indicating that 
S165A disrupts the nuclear co-localization of YBX1 and 
P65 in 293 cells.
Expression of YBX1 increases with colon cancer 
progression
As YBX1 is a known oncogene, we further 
examined the expression levels of YBX1 in different types 
of cancers. GeneNote data (Figure 6A) indicated that the 
expression level of YBX1 is increased in the cancers of the 
thymus, bone marrow, spleen, whole blood, brain, kidney, 
lung, colon, bladder, liver, pancreas, prostate, skin, breast, 
salivary gland, ovary, and cervix, with strikingly elevated 
levels of YBX1 in colon cancer. Oncomine data also 
indicated that out of the 37 colon cancer patient specimens, 
the majority showed increased expression of YBX1 
(Figure 6B). We further carried out tissue microarray 
[TMA] analysis [US Biomax Inc., Rockville, MD] for 
YBX1 in specimens from both normal and different stages 
of colon cancer by using immunohistochemical [IHC] 
methods. Compared with normal specimens, a marked 
increase of YBX1 expression was observed in progressive 
stages of colon cancer (Figure 6C). Interestingly, a 
dramatic increase of YBX1 expression was also observed 
in tissue samples isolated from polyps compared with the 
normal specimens. Overall, this data strongly suggested 
that YBX1 potentially plays a very important role in 
colon cancer development, and possibly in the transition 
between polyps and cancerous cells as well.
Hypothetical model
By using human protein research domain software, 
we predicted that S165 of YBX1 is phosphorylated by 
casein kinase II [CKII] (Figure 7A). Collectively, based 
on all the data we have presented, we hypothesize that 
in the presence of an NF-κB activating cytokine, such as 
IL-1β, the IκB kinase phosphorylates IκBα, which leads 
to the degradation of IκB. The free P65/P50 heterodimer 
then migrates to the nucleus to bind to κB binding sites on 
the promoters of specific genes, leading to their activation. 
Meanwhile, IL-1β leads to the activation of CKII which 
then phosphorylates YBX1 on S165. This event further 
activates NF-κB possibly by increasing the translocation 
of NF-κB into the nucleus and enhancing NF-κB DNA 
binding ability, thereby promoting NF-κB-inducible gene 
expression (Figure 7B). 
DISCUSSION
Aberrant activation of the NF-κB signaling pathway 
is associated with most cancers [15]. NF-κB regulates 
expression of genes involved in the cell cycle, apoptosis, 
immune response, and tumorigenesis [14]. Thus, targeting 
this pathway holds tremendous therapeutic potential in 
treating cancer and other inflammatory diseases. It is also 
now a widely accepted view that YBX1 is an oncoprotein 
that promotes the most of the famous ‘hallmarks of cancer’ 
proposed by Hanahan and Weinberg [6]. However, to date, 
there are no reports regarding the direct crosstalk between 
NF-κB and YBX1.
In this study, we showed that overexpression of 
WT-YBX1 could activate NF-κB, and this effect is 
dramatically enhanced when cells were further treated 
with NF-κB activating cytokines such as IL-1β. Moreover, 
using mass spectrometry we discovered a previously 
unknown phosphorylation of Ser165 on YBX1. We proved 
that mutation of S165 to “A” greatly reduced the NF-κB 
activating ability of YBX1, and therefore, greatly reduced 
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Figure 6: YBX1 is overexpressed in many types of cancer, especially in colon cancer. A. GeneNote data, showing the 
expression level of YBX1 in different types of cancers; colon cancer shows very high expression level of YBX1. B. Oncomine data, 
showing the comparison of the expression of YBX1 in 37 colon cancer vs. normal datasets. The intensity of red color corresponds to 
the level of expression of YBX1, indicating that YBX1 is overexpressed in the specimens from many colon cancer patients. C.. Tissue 
microarray assay of YBX1, top panel, showing tissue sections stained with anti-YBX1 antibody, demonstrating elevated levels of YBX1 
staining in polyps and different stages of colon cancer as compared to the normal tissue. Magnification fold: 20X. Bottom panel, showing 
relative expression of YBX1 across different stages of colon samples, polys and tumors showed relatively higher levels of YBX1 expression 
than that of normal adjacent tissue. Abbreviations: Met, metastasis; NAT, normal adjacent tissue.
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Figure 7: Hypothetical Model. A. Casein kinase II is predicted to be the kinase that is responsible for the phosphorylation of S165 
of YBX1. B. Model, hypothesizing that in the presence of external stimuli like IL-1β, the IκB kinase phosphorylates IκBα. This leads to 
the degradation of IκB. The free P65/P50 heterodimer then migrate to the nucleus to bind to κB-binding sites on the promoters of specific 
genes, leading to their activation. On the other hand, IL-1β has also been shown to stimulate YBX1 activity. We hypothesize that stimulation 
with IL-1β activates CKII, which then promotes phosphorylation of YBX1 on S165 which then leads to increased activation of NF-κB, 
possibly by increasing the DNA binding ability of NF-κB, and enhancing the expression of NF-κB-inducible genes, thus promoting cancer 
progression.
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cell growth and colony formation in colon cancer HT29 
cells. 
Sutherland and colleagues found that S102 of YBX1 
is phosphorylated upon treatment with IGF1. Mutation of 
the S102 site of YBX1 inhibited tumor growth via the 
Akt/PKB pathway in breast cancer [10]. It is interesting 
that we did not observe phosphorylation of S102 in IL-
1β treated cells by either mass spectrometry or western 
analysis, suggesting that different cytokines could lead to 
differential phosphorylation in cancer cells. Different from 
IGF1, IL-1β is a very classical NF-κB activating cytokine, 
which is frequently found in the tumor environment. The 
identification of S165 phosphorylation by IL-1β expands 
our current knowledge and provides deeper insight into the 
complicated phosphorylation pattern of YBX1. 
Moreover, we reported the interesting and important 
connection between YBX1 modification and NF-κB 
activation. To our knowledge, this is the first report to 
suggest that YBX1 is a direct activator of NF-κB, and 
S165 phosphorylation is critical for its NF-κB activating 
function. 
Importantly, GeneNote data, Oncomine data, 
together with our tissue microarray data (Figure 6) 
strongly support the overexpression of YBX1 in cancer, 
particularly, in colon cancer. Our tissue microarray 
data suggested that YBX1 is overexpressed not only in 
different stages of colon cancer specimens but also in 
polyps, indicating a potential role YBX1 may play in early 
stage of colon cancer development. 
By using the Human Protein Reference Database, 
we predicted that CKII may be the kinase to phosphorylate 
YBX1 on S165. CKII is an important kinase that has been 
linked to the activation of NF-κB by reactive oxidase 
species [ROS] [23] as well as to the NF-κB activation in 
pancreatic β cells and cancers such as glioblastoma [24, 
25]. In addition, CKII was reported to be involved in 
cell cycle control and DNA repair and has been shown 
to activate the Wnt signaling pathway. In cancer, Wnt has 
been implicated in promoting the epithelial-mesenchymal 
transition that contributes to the development of the 
cancer phenotype [26]. YBX1 has been shown to bind 
to the promoters of a number of Wnt pathway proteins. 
Hence, further research involving validating the role of 
CKII in our model could help shed light on the mechanism 
underlying S165 phosphorylation of YBX1 and help to 
better understand the crosstalk between different signaling 
pathways that are linked through the activation of YBX1 
by S165 phosphorylation.
Our current study has great significance by linking 
two well-known cancer culprits: NF-κB and YBX1. 
Although targeting NF-κB is critical to cancer therapy, 
due to its critical role in normal cellular functions, it is 
generally not a wise strategy to directly target NF-κB 
in cancer. For this reason, targeting pathway-specific 
regulators of NF-κB would seem to be a more favorable 
approach in this regard. 
Our current study emphasizes that phosphorylation 
of S165 on YBX1 is critical for the regulation of a 
subgroup of NF-κB target genes; therefore, modulation 
of this activity by blocking S165 phosphorylation of 
YBX1 could be a promising approach for inhibiting tumor 
growth. Furthermore, although our study is mainly focused 
on colon cancer, it is highly possible that phosphorylation 
of S165 of YBX1 also plays an important role in other 
types of cancer as well. This would also be a potential new 
aspect we would like to explore in the future.
MATERIALS AND METHODS
Cell lines and antibodies
The 293 cell line has been described previously 
[19]. The HT29 colon cancer cell line was purchased 
from the American Tissue Culture Collection [ATCC, 
Manassas, VA, USA] and was cultivated in RPMI-1640 
media with 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 10% fetal calf serum. The following antibodies were 
obtained from commercial sources: anti-YBX1 [Abcam, 
Cambridge, MA, USA], anti-NF-κB p65 [Santa Cruz 
Biotechnology Inc. Dallas, Texas, USA], anti-IκBα [Santa 
Cruz Biotechnology Inc. Dallas, Texas, USA], and anti-β-
actin [Sigma-Aldrich, St. Louis, MO, USA]. 
Construction of stable overexpressing WT-YBX1, 
mutant S165A-YBX1, and shYBX1 in HT29 cells
 Flag-tagged WT-YBX1 cDNA was amplified by 
reverse transcription from total mRNA derived from 
293 cells. Sequence was confirmed and then cloned 
into pLVX-IRES-puro vector [19]. Mutation of S165 
residue to A was generated using QuikChange II XL 
Site-Directed Mutagenesis Kit following manufacturer’s 
protocol (Agilent Technologies, Inc., Santa Clara, CA). 
The mutated site was then confirmed by sequencing. 
The shRNA pool against YBX1 was purchased from 
Sigma-Aldrich, St. Louis, MO, USA. All cell lines were 
generated using either 293 or HT29 colon cancer cell lines. 
To generate the stable cell lines, the lentiviral plasmid 
containing the DNA of interest or shRNAs were transected 
into a 293T packaging cell line to produce viruses which 
then were collected and used to infect 293 or HT29 cells. 
48 h after infection, cells were further selected with 1μg/
mL of puromycin, since the lentiviral vector construct was 
comprised of a puromycin resistance gene. Expression of 
the respective constructs was confirmed with Western 
Blotting using specific antibodies.
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Transfections and luciferase assays
 Constructs were transfected into cell lines using the 
Lipofectamine and PLUS Reagents [Life Technologies 
Invitrogen, Grand Island, NY]. For NF-κB luciferase 
assays, the κB-luciferase construct p5XIP10 κB [20] was 
transfected transiently into the cells, and luciferase activity 
was assayed 48 h later. A β-galactosidase construct was 
co-transfected to normalize for transfection efficiency. 
Transfections and luciferase assays were carried out as 
previously described [21]. 
Western analyses
Cells were cultured to ∼95% confluence, and 
samples were collected and assayed by the Western 
method as described previously [20]. Different antibodies 
were used based on different experiments described in the 
text.
Electrophoresis gel mobility assay [EMSA]
 The oligomer used for the NF-κB binding site 
was 5’AGTTGAGGGGACTTTCCCAGGC-3’ [Santa 
Cruz Biotechnology, Inc. Dallas, TX]. It was labeled 
with [γ-32P] ATP by the polynucleotide kinase method, 
following the protocol provided by Promega Corporation 
[Madison, WI]. Whole cell lysates were prepared and 
analyzed essentially as previously described [20]. 
Cell growth and soft agar assays
 HT29 cells overexpressing WT-YBX1, S165A-
YBX1, and shRNA-YBX1 knockdown cell lines were 
plated at 2 X 104 cells/well in a six-well plate with 3ml 
RPMI-1640 media. Cells were seeded in triplicates and 
counted at different time points i.e. day 2, 4, 6, 8 using 
a cell counting chamber. For soft agar assays, type VII 
agarose [Sigma] was autoclaved and mixed with RPMI-
1640 cell growth medium. Cell culture dishes were coated 
with 1.2% type VII agarose as the bottom layer. Cells were 
resuspended in 0.6% of type VII agarose, and plated on 
top of the bottom layer. Cells were cultured for 2-3 weeks 
before being checked under a microscope, measured and 
quantified with the aid of ImageJ software [http://imagej.
nih.gov/ij/].
Mass spectrometry [MS] experiments
Ten 15-cm plates of 293C6 cells with the stably 
expressed WT-YBX1-Flag protein were cultured to 80% 
confluence. Five were used as control, and the other 5 
plates were treated with IL-1β for 1 h. Cells were then 
lysed with coimmunoprecipitation buffer [1% Triton 
X-100, 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
EDTA, 1 mM sodium orthovanadate, 20 μM aprotinin, 
and 1 mM phenylmethanesulfonyl fluoride and pepstatin 
A]. After spinning the debris for 10 min at 4°C, the 
supernatant solution was incubated with EZview Red 
anti-Flag M2 affinity gel overnight at 4°C. Gel beads were 
washed with 20 volumes of Immunoprecipitation buffer 
[21], with rotation at 4°C for 5 min each time. Protein 
was eluted with Flag peptide [Sigma], following Sigma’s 
standard protocol. The supernatant solution was mixed 
with 5XSDS sample loading buffer, boiled for 5 min, and 
separated in a 10% Tris-HCl SDS/PAGE gel [21]. The gel 
was then treated with fixing buffer [50% ethanol, 10% 
acetic acid] for 20 min and washed with distilled water for 
1 h before being stained with GelCode Blue stain [Pierce] 
overnight. The gel was destained with distilled water for 2 
h before analysis by MS.
Protein in-gel digestion
Gel pieces cut from SDS/PAGE gels were excised 
and subjected to in-gel tryptic digestion. The excised 
bands were washed twice with 100 mM ammonium 
bicarbonate containing 50% acetonitrile for 1 h and twice 
with acetonitrile for 10 min. The proteins in the gels were 
then treated with 20 mM Dithiothreitol [DTT] at room 
temperature for 30 min followed by 50 mM iodoacetamide 
for 30min in 100mM ammonium bicarbonate. After the 
treatment, the reagents were removed, and the gel pieces 
were washed with 100 mM ammonium bicarbonate and 
then dehydrated in acetonitrile. The dried gel pieces 
were then rehydrated in 50 mM ammonium bicarbonate 
containing sequencing grade modified trypsin for 
overnight digestion. Tryptic peptides were extracted from 
the gel with 50% acetonitrile in 5% formic acid.
Tandem mass spectrum analysis
The proteolytic digests were analyzed using a LTQ 
Orbitrap XL linear ion trap mass spectrometer [Thermo 
Fisher Scientific] coupled with Ultimate 3000 HPLC 
system [Dionex]. The reverse-phase C18 column [0.075 
× 150 mm, Dionex] was equilibrated with 0.1% formic 
acid 4% acetonitrile [vol/vol], and the proteolytic digests 
were injected on it. A linear gradient of acetonitrile from 
4% to 40% in water in the presence of 0.1% formic acid 
over a period of 45 min was used at a flow rate of 300 
nL/min. The spectra were acquired by data-dependent 
methods consisting of a full scan [m/z 400-2,000] and 
then tandem MS on the five most abundant precursor ions. 
The previously selected precursor ions were scanned once 
during 30 s and then were excluded for 30 s. The obtained 
data were submitted to Mascot software [Matrix Science] 
to search for phosphorylated residues on the YBX1 
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protein. The tandem mass spectra of the possibly modified 
peptides were further interpreted manually.
Illumina microarrays
 RNA [250 ng] was reverse-transcribed into cDNA 
and labeled with biotin-UTP using the Illumina TotalPrep 
RNA Amplification Kit [Ambion/Applied Biosystems]. 
The amount of cDNA was determined by using a 
nanodrop spectrophotometer, and the cDNA quality [size 
distribution] was further analyzed in a 1% [wt/vol] agarose 
gel. cDNA was hybridized to Illumina Human Ref-v3 
v1 Expression BeadChips and scanned in a BeadArray 
Reader using standard protocols [provided by Illumina]. 
Illumina’s BeadStudio software was used for data analysis.
Immunofluorescence [IF] experiment
Coverslips were coated with 0.1% sterile gelatin 
for 2 h and dried for 30min at R.T. 1x105 cells were then 
seeded onto coverslip per well in a 24-well plate. After 
overnight culture, cells were treated with or without IL-1β 
for 1h to continue with IF experiments. Cells were fixed 
with 4% of formaldehyde for 30min and then blocked 
with blocking buffer for 10min at R.T. Coverslips were 
further probed with anti-Flag antibody for flag-tagged 
WT-YBX1 or S165A and Alexa Fluor 488 [green] goat 
anti-mouse IgG [Life Technologies]. For double staining, 
anti-Flag antibody for Flag-tagged WT-YBX1 or S165A 
and anti-p65 for p65 were used then further probed with 
Alexa Fluor 488 [green] goat anti-mouse IgG and Alexa 
Fluor 680 [red] goat anti-Mouse IgG [Life Technologies], 
respectively. Before sealing the coverslips, mounting 
media with DAPI was used to stain the nucleus. The 
slides were examined under Nikon Eclipse 80i with 60x 
magnification.
Immunohistochemistry [IHC] experiment
Colon cancer tissue microarray comprising 
matched normal adjacent and various clinical stages of 
colon carcinoma tissue was obtained from US Biomax 
Inc. [Rockville, MD]. Hematoxylin-eosin [H&E] was 
performed using routine methods. The tissue microarray 
were blocked with protein blocking solution [Dako 
Corp.] for 30 min. All subsequent staining steps were 
performed using the Dako FLEX SYSTEM on an 
automated Immunostainer. Incubations were done at room 
temperature and Tris buffered saline plus 0.05% Tween 20, 
pH 7.4 [Dako Corp] was used for all washes and diluents. 
Thorough washing was performed after each incubation. 
Anti-YBX1 primary antibody was used to detect YBX1 
localization. Horseradish peroxidase conjugated secondary 
antibody was then used, followed by addition of the 
chromogen, which produced a brown precipitate at the site 
of secondary antibody binding. The Aperio whole slide 
digital imaging system was used for imaging. The system 
imaged all slides at 20X.
Statistical analysis
 Statistical analysis was performed using Prism 6 
software [GraphPad, San Diego, CA]. The data represent 
the mean ± SD from three independent experiments. 
A two-tailed Student’s t test was used while comparing 
two means and to test for significant differences between 
relative luciferase activity and relative gene expression in 
different groups. All statistics were calculated on triplicate 
experiments. For all statistics, P < 0.05 was considered to 
be statistically significant.
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